EraGen and Bayer in License Agreement

By leveraging isobases, the test substantially reduces the time for CF multi-mutation analysis compared to other testing systems. The test will allow the customers of Bayer Healthcare to enhance their level of CF clinical testing by reducing errors, providing faster turnaround, and lessening labor needs.

"Automated genetic diagnostics assays, including those for cystic fibrosis, are vital for the laboratory to take advantage of clinical progress, while maintaining lab efficiencies and providing timely, reliable clinical information,” stated Tony Bihl, president of Bayer HealthCare's Diagnostics Division.

The agreement between EraGen and Bayer also provides Bayer with additional rights, enabling the company to expand its presence in the genetics-based diagnostic testing market with a number of assays for other diseases.





Related Links:
EraGen
Bayer Diag.